Analyst consensus rating
Xilio Therapeutics Analyst Rating: none
XLO is rated none by 1 analysts with a $20.00 target. As of 2026-09-02.
Direct answer
Xilio Therapeutics's consensus rating is none.
1 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $20.00.
Forecast evidence checked September 2, 2026.
Get free Xilio Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $8.88
- Average price target
- $20.00
- High price target
- $20.00
- Low price target
- $20.00
- Low target gap
- +125.2%
- Target upside
- +125.2%
- High target gap
- +125.2%
- Target range width
- 0%
- Consensus rating
- none
- Analysts
- 1
- Evidence date
- September 2, 2026
- Valid through
- September 9, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Xilio Therapeutics?
Xilio Therapeutics has a verified none consensus. The same dataset has an average price target of $20.00.
How far are Xilio Therapeutics's low and high targets from the recorded price?
The low target implies +125.2%, while the high target implies +125.2%.
How many analysts are included in Xilio Therapeutics's consensus?
The verified consensus includes 1 analysts.
How is Xilio Therapeutics's target upside or downside calculated?
The average target of $20.00 is divided by the recorded price of $8.88, then one is subtracted to produce +125.2%. This does not guarantee a future return.
When was Xilio Therapeutics's analyst forecast verified?
The data was verified on 2026-09-02. The dataset is valid through 2026-09-09.